Aiming to support drug developers in issues related to market insights, engagement, and access, Synaptiq enters the market backed by three consultancy agencies.
Acquisition of Clindata’s human health biometrics division is expected to increase Synteract’s geographical footprint along with the adaptability of its biometrics services solutions.
Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
Saama Technologies today announced that it has signed a definitive agreement to acquire Comprehend Systems, creating an ‘enhanced suite of complementary capabilities’ to ‘facilitate more rapid drug development,’ says company executives.
University of Rochester Medical Center joined the global health research network aiming to ‘expand its access to advanced clinical trials’, TriNetX announced.
M&A is a huge part of the CRO space. Inorganic growth has long been the go-to strategy for any CRO and we’re never surprised to see this month’s latest deal. However, I’d like to challenge the idea that this is always the best way to grow a CRO business.
Accelovance and Linical are merging to create a contract research organization (CRO) with a global footprint in response to the need for large-scale, multinational clinical trials.
At DCAT Week, contract manufacturing and development companies from across the globe shared updates and news – from multi-million dollar investments to new business structures and areas of focus.
With fewer global mid-sized contract research organizations (CRO) through consolidation, some stakeholders are expressing concern that the industry could become a monopoly – “we may be getting there,” one expert said.
INC Research/inVentiv Health is starting the new year with a rebrand after merging to create one of the largest biopharmaceutical outsourcing providers in 2017.
CTI Clinical Trial and Consulting Services (CTI) and Eurotrials have consolidated to create a full-service contract research organization (CRO) with a global footprint.
“Bring Your Own Device” (BYOD) in clinical trials will be a “critical component” of future research says Bracket CEO following the company’s acquisition of mProve Health.
Niche, small-scale CROs can stand their own – despite a predicted increase in consolidation among small-sized contract services firms – says Clinical Trial Consultants (CTC) and data-focused Quanticate.
Pharmaron’s acquisition of Xceleron further supports early discovery, preclinical and clinical development with expanded radiolabeled sciences capabilities.
Recipharm receives approval to buy Kemwell’s Indian operations and PolyPeptides completes the acquisition of Lonza’s peptide business. Welcome to in-Pharmatechnologist’s 2017 M&A round-up.
